Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00310037 · ClinicalTrials.gov registry record · Phase 2

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
151
Enrollment target
20
Study locations

NCT00310037: Completed Phase 2 study of Mantle Cell Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

NCT00310037 is a Phase 2 study of Mantle Cell Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 151 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00310037, a Phase 2 study of Mantle Cell Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
151 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase II trial studies how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with an autologous stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib after combination chemotherapy, monoclonal antibody therapy, and an autologous stem cell transplant may kill any remaining cancer cells or keep the cancer from coming back.

Primary Outcome

Progression free survival (PFS) rate at 18 months was defined as the proportion of patients that were alive and progression-free 18 months after registration into the study. The Kaplan-Meier method of 18 month progression-free survival was calculated..

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • DRUG bortezomib

Study Locations (20)

Illinois

  • Illinois CancerCare - Bloomington - Bloomington
  • St. Joseph Medical Center - Bloomington
  • Graham Hospital - Canton
  • Illinois CancerCare - Canton - Canton
  • Illinois CancerCare - Carthage - Carthage
  • Memorial Hospital - Carthage
  • University of Chicago Cancer Research Center - Chicago
  • Eureka Community Hospital - Eureka
  • Illinois CancerCare - Eureka - Eureka
  • Galesburg Clinic, PC - Galesburg
  • Illinois CancerCare - Galesburg - Galesburg
  • Illinois CancerCare - Havana - Havana
  • Mason District Hospital - Havana
  • Illinois CancerCare - Kewanee Clinic - Kewanee
  • Illinois CancerCare - Macomb - Macomb
  • McDonough District Hospital - Macomb
  • Illinois CancerCare - Monmouth - Monmouth
  • OSF Holy Family Medical Center - Monmouth
  • BroMenn Regional Medical Center - Normal

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Trial Details

FieldValue
Enrollment Target 151 participants
Start Date 2006-06
Est. Completion 2022-06
Phase Phase 2
Alliance for Clinical Trials in Oncology

446 total trials

What the finished NCT00310037 record still lists

NCT00310037 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (47% higher).

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.

NCT00310037 names 20 study sites across 2 states, led by Illinois, California.

Frequently Asked Questions

What is clinical trial NCT00310037 about?

NCT00310037 is a clinical study titled "Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma". This randomized phase II trial studies how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell...

What is the current status of trial NCT00310037?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2006-06. Estimated completion is 2022-06.

What conditions does trial NCT00310037 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT00310037?

The interventions under investigation include: bortezomib (DRUG).

Who is sponsoring clinical trial NCT00310037?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00310037 being conducted?

This trial has 20 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00310037's enrollment target sits among peer trials

151 19th of 102 higher than 84 of 102 other Mantle Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01409161 · 151 participants · Phase 2

    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

  • NCT04245397 · 151 participants · Phase 1

    Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  • NCT05761223 · 151 participants · Phase 1

    A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

  • NCT07195656 · 151 participants · NA

    Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00310037, the US trial registry maintained by the National Library of Medicine. NCT00310037 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.